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Aldosterone Synthase Gene 




Aldosterone, the principal human mineralocorticoid, acts mainly for sodium 
reabsorption with potassium and hydrogen excretion. The adrenal cortex is the 
main site of aldosterone synthesis; however, extra-adrenal tissues such as the 
nervous, the cardiovascular, and the adipose tissues may be involved. Therefore, 
its action is mediated via endocrine as well as paracrine or autocrine mode. 
Aldosterone receptors are distributed extensively in the renal distal nephron and 
other sites, such as the heart, brain, vessels, and liver. The aldosterone synthase 
catalyzes the conversion of deoxycorticosterone finally to aldosterone. CYP11B2 
gene occupies human chromosome 8q21-22 with nine exons and eight introns. 
Alteration of aldosterone synthase gene that is attributable to genetic polymor-
phisms can affect its transcription leading to several cardiovascular disorders such 
as essential hypertension, myocardial infarction, cardiomyopathies, and atrial 
fibrillations. Accordingly, it is important to illustrate these polymorphisms and the 
mechanisms by which they alter the aldosterone synthase gene and produce cardio-
vascular dysfunctions.
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1. Introduction
CYP11B2 enzyme is one of the enzymes in the pathway of steroidogenesis and 
responsible for the catalysis of the last three steps in the aldosterone biosynthetic 
cascade. It is encoded by CYP11B2 gene located on human chromosome 8q21-22. 
The genetic element of cardiovascular disorders has been emerged as a risk factor 
for the progression of these disorders. Among these genetic elements, CYP11B2 
genetic variants and haplotypes play a pivotal role in the susceptibility, progres-
sion, survival, and therapeutic response of many cardiovascular disorders such as 
hypertension, coronary heart disease (CAD), atrial fibrillation (AF), cardiomy-
opathy, heart failure (HF), and other disorders. It was suggested to influence the 
cardiovascular system via alteration of aldosterone production, which acts either 
directly on the heart or systemically via stimulating sodium and water reabsorption 
and increasing the blood pressure.




Aldosterone is the main human mineralocorticoid. The main site of aldoste-
rone synthesis is the zona glomerulosa (ZG) in the adrenal cortex. However, it 
can be produced by extra-adrenal tissues such as the central nervous system, the 
cardiovascular system, and the adipose tissue with a non-detectable physiological 
relevance and a small contribution to circulating aldosterone levels [1].
It is synthesized from cholesterol by a group of enzymatic cascade 
(Figure 1). First, cholesterol is translocated into the mitochondria across its 
wall mediated by steroidogenic acute regulatory protein (StAR). Cholesterol is 
then converted to pregnenolone, through three reactions, a 20α-hydroxylation, 
a 22-hydroxylation, and cleavage of the bond between C-20 and C-22 catalyzed 
by the CYP11A1 cleavage enzyme, encoded by the CYP11A1 gene on human 
chromosome 15 [2].
The produced pregnenolone is then released into the cytoplasm where it under-
goes dehydrogenation of the 3β-hydroxyl group and isomerization of the double 
bond at C-5 to Δ4 by 3β-hydroxysteroid dehydrogenase (3β-HSD) and converted 
to progesterone [3]. Furthermore, progesterone undergoes 21-hydroxylation by the 
CYP21A enzyme encoded by CYP21A mapped to human chromosome 6p21·3 and 
located on the cytoplasmic surface of the smooth endoplasmic reticulum, generat-
ing 11-deoxycorticosterone (DOC). Then, DOC passes through three consecu-
tive reactions catalyzed by aldosterone synthase enzyme, located on the inner 
mitochondrial membrane and encoded by the CYP11B2 gene, 11β-hydroxylation 
to corticosterone, 18-hydroxylation to 18-hydroxycorticosterone, and finally 
18-methyloxidation to aldosterone [4].
2.2 Mechanism of action of aldosterone
The action of aldosterone is mediated though mineralocorticoid receptor (MR), 
a specific nuclear receptor that comprises N-terminal domain, DNA-binding 
domain, and C-terminal ligand-binding domain. It is present as a hetero-oligomeric 
Figure 1. 
Enzymatic cascade of the aldosterone biosynthesis.
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complex with heat-shock proteins in the cell. Once aldosterone binds to its receptor, 
it undergoes a conformational change resulting in dissociation of the associated 
proteins, dimerization, and nuclear translocation [5]. This hormone receptor 
complex combines with the steroid responsive elements in the 5′-UTR of aldoste-
rone-responsive genes with the release of aldosterone-induced proteins (AIP) that 
enhances or suppresses gene transcription [4].
The serine threonine glucocorticoid regulated kinase 1 (sgk1), which is one of 
the AIP proteins, has been phosphorylated and activated by the aldosterone, which 
in turn phosphorylates epithelial sodium channel (ENaC) regulatory protein, 
known as Nedd4–2, reducing its binding to ENaC [6] with subsequent increase in 
ENaC density and stability at the apical membrane resulting in increased ENaC-
dependent Na+ reabsorption [7]. The glucocorticoid-induced leucine zipper (GILZ) 
and the corticosteroid hormone-induced factor (CHIF) are also AIP proteins. GILZ 
interacts with aldosterone inhibiting the ERK signaling pathway, thus liberating 
ENaC from Nedd4 proteins; accordingly, its action in blocking sodium reabsorption 
is inhibited [8]. CHIF may affect the baso-lateral Na/K-pump, resulting in increased 
sodium reabsorption with potassium or hydrogen ion excretion (Figure 2) [9]. 
Aldosterone also exerts a genomic action via modulating the gene expression and 
subsequent protein production that result in a lag time of 1–2 h before a noticeable 
change in target cell activity occur [10].
2.3 Physiological action of aldosterone
As the kidneys are the main site of action for aldosterone, MRs are confined 
mainly in high concentration to the renal distal convoluted tubules and collecting 
duct controlling the apically located epithelial sodium channels at their luminal 
cells. Mineralocorticoid receptors also exist in other epithelial sites, such as the 
colon, sweat gland ducts, salivary glands [11], and non-epithelial sites including 
Figure 2. 
Mechanism of action of aldosterone in epithelial cells. Abbreviations: ENaC, epithelial sodium channel; HRE, 
hormone response element; GILZ, glucocorticoid-induced leucine zipper protein; Nedd4-2, neuronal precursor 
cell-expressed, developmentally down-regulated protein; Sgk1, serine threonine glucocorticoid regulated kinase 
1; CHIF, channel-inducing factor; MR, mineralocorticoid receptor.
The Recent Topics in Genetic Polymorphisms
4
myocytes, endocardium of the heart, brain, vascular smooth muscle, liver, and 
leukocytes [12]. The main action of aldosterone is stimulation of sodium reabsorp-
tion in the kidney and at other secretory epithelial sites with excretion of potassium 
and hydrogen ions [13] possibly mediated via increasing the opening periods of the 
existing ion channels or increasing their number [14].
In cardiovascular system, aldosterone promotes myocardial hypertrophy 
and fibrosis via increasing collagen I synthesis in cardiac fibroblasts and also 
elevating endothelin receptor numbers that further increases collagen synthesis 
[15]. So, increased expression of mineralocorticoid receptors in the heart may 
result in left-ventricular hypertrophy in normotensive subjects [16]. Aldosterone 
also stimulates vascular constriction via enhancing the pressor response to 
catecholamines and impairing the vasodilatory response to acetylcholine or by 
upregulation of angiotensin II receptors [4]. Also, aldosterone excess can trigger 
collagen deposition in blood vessels, enhancing vascular remodeling and reducing 
compliance [17]. In the CNS, it appears to regulate blood pressure, salt appetite, 
and sympathetic tone [4].
Under normal circumstances, it is likely that cardiac MRs are occupied by glu-
cocorticoid due to its higher circulating concentration exerting antagonistic effect 
attenuating the rise in blood pressure and the cardiac fibrosis caused by aldosterone 
alone [18].
3. Cytochrome P450 11B2 (CYP11B2)
3.1 Reaction catalyzed
CYP11B2 enzyme is located in the inner mitochondrial membrane. Aldosterone 
synthesis from 11-deoxycorticosterone is catalyzed by CYP11B2 enzyme, more 
commonly referred to as aldosterone synthase, which catalyzes three sequential 
reactions, each utilizing one molecule of NADPH, one molecule of oxygen, and the 
mitochondrial electron transfer system. The three sequential reactions are as fol-
lows: the 11β-hydroxylation of 11 deoxycorticosterone, the hydroxylation of carbon 
18, followed by oxidation of the carbon 18 hydroxyl group to yield the carbon 18 
aldehyde group resulting in the formation of aldosterone (Figure 3) [19].
3.2 Molecular structure
CYP11B2 gene is located on human chromosome 8q21-22. It consists of nine 
exons, eight introns, and comprises about 7 kb (Figure 4). Its coding region is 95% 
identical, and its intronic region is 90% identical with CYP11B1. However, its 5′ 
untranslated region is different from that of CYP11B1 gene, thus accounting for the 
differences in regulation and expression pattern for each gene [20].
3.3 Protein structure
The human CYP11B2 proteins are located in the inner mitochondrial mem-
brane and consist of 503 amino acids, including a 24-residue N-terminal mito-
chondrial targeting sequence. At the protein level, the enzyme is 93% homologous 
with CYP11B1 reflecting its shared 11β-hydroxylase and 18-hydroxylation activity. 
Only 37 amino acids differ between them which accounts for their different func-
tions. Although CYP11B1 and B2 consist of the same number of amino acid, the 
apparent molecular mass of the human enzymes was reported as 51 and 49 kDa, 
respectively [20].
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3.4 Tissue-specific expression
Expression of CYP11B2 is limited to the adrenal cortex and appears to be exclu-
sively in adrenal zona glomerulosa cells [21].
3.5 Regulation of CYP11B2 expression
Adrenal steroidogenesis is under both acute and chronic regulation by tropic 
hormones. The acute response occurs within minutes and involves the mobilization 
of cholesterol from intracellular stores to the mitochondrial membrane in response 
to ACTH, angiotensin II, K+, and their respective intracellular messenger pathways. 
Figure 3. 
Enzymatic reactions catalyzed by CYP11B2 enzyme.
Figure 4. 
Schematic diagram of the exonic-intronic arrangement of the CYP11B2 genes.
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The chronic response takes several hours and involves the transcription of the genes 
encoding the steroidogenic enzymes [22].
3.5.1 Signaling pathways that regulate aldosterone production
3.5.1.1 ACTH
Adrenocorticotrophin (ACTH) is a 39 amino acid peptide released from the 
anterior pituitary in pulsatile and diurnal rhythm with the highest levels in the 
morning and the lowest at night [23]. ACTH exerts its effects by binding to its 
receptor (ACTH-R), a G-protein-coupled receptor. ACTH acutely stimulates 
aldosterone secretion but in the long term has an inhibitory effect on CYP11B2 gene 
expression and aldosterone levels [24].
Acute stimulation of aldosterone production has suggested to be mediated via 
activation of StAR protein production. Also, ACTH after binding to its receptor can 
activate adenylate cyclase, resulting in an increased intracellular cAMP concentra-
tion, activation of protein kinase A (PKA), and calcium influx via calcium channels 
(Figure 5) [25].
On the other hand, chronic ACTH stimulation may depress serum aldo-
sterone level as cyclic AMP, the second messenger for ACTH, desensitizes 
adrenocortical cells to angiotensin II by causing a reduction in the expression 
of angiotensin II receptors. ACTH may also decrease aldosterone produc-
tion by stimulating the expression of CYP11B1 and CYP17, thereby resulting 
in a removal of precursors from the aldosterone pathway and using them to 
Figure 5. 
Intracellular mechanisms of angiotensin II, K+ and ACTH influencing gene expression. Abbreviations: ER, 
endoplasmic reticulum; AT1-R, angiotensin 1 receptor; PLC, phospholipase C; PKA, protein kinase A; IP3R, 
inositol triphosphate receptor; IP3, inositol triphosphate; CaMK, calmodulin kinase; SF-1, steroidogenic factor 
1; CREB, cAMP regulatory element response element; ACTH, adrenocorticotrophic hormone.
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synthesize cortisol. ACTH appears to specifically induce the proliferation of 
zona fasciculata cells while recruiting and transforming glomerulosa cells into 
fasciculata-like cells [26].
Under normal circulating ACTH levels, the glomerulosa maintains CYP11B2 
expression by at least two mechanisms. First, angiotensin II inhibits ACTH-
stimulated cAMP production in glomerulosa but not fasciculata cells. Second, 
the glomerulosa expresses a type of adenyl cyclase that is inhibited by increasing 
intracellular Ca2+, the second messenger for both angiotensin II and K+ [27].
3.5.1.2 Angiotensin II
Angiotensin II is thought to stimulate aldosterone synthesis as result of sodium 
depletion and extracellular fluid volume reduction through various intracellular 
signaling pathways. However, the best characterized pathway is the activation of 
phospholipase C (Figure 5). It is mediated by acting on angiotensin 1 (AT1) recep-
tor, a specific G-protein-coupled receptor that activates phospholipase C. Once 
activated, phospholipase C hydrolyses phosphatidyl inositol 4,5-biphosphate (PIP2) 
to 1,4,5 inositol triphosphate (IP3) and 1,2-diacylglycerol (DAG) resulting in release 
of Ca2+ from intracellular stores and activation of protein kinase C (PKC), respec-
tively. The increased intracellular Ca2+ concentration activates calmodulin and Ca2+/
calmodulin-dependent protein kinases (CaM kinases) [28, 29] to phosphorylate and 
activate transcription factors as activating transcription factor 1 (ATF-1), cAMP-
response-element binding protein (CREB), nerve growth factor IB (NGFIB), and 
nuclear receptor related 1 protein (NURR1) that combined to specific cis-acting 
series in the 5′ region of CYP11B2 [30]. The acute stimulation mediated by angio-
tensin II can stimulate rapid aldosterone synthesis either de novo or from interme-
diate compounds in the steroidogenic pathway. However, chronic stimulation may 
lead to ZG hypertrophy and hyperplasia with increased CYP11B2 expression and 
subsequent aldosterone secretion [31].
3.5.1.3 Potassium
The level of potassium affects renin secretion as well as having a direct 
effect on the adrenal cortex to increase aldosterone secretion. Increased 
extracellular K+ (like angiotensin II) stimulates aldosterone secretion through 
an increase in intracellular Ca2+ and activation of calmodulin kinases with 
consequent phosphorylation of transcription factors leading to stimulation of 
CYP11B2 gene transcription. Potassium signaling is mediated through mem-
brane depolarization, leading to an influx of calcium through T and L-type 
channels (Figure 5) [32].
3.5.2 Transcriptional regulation of CYP11B2 gene
As mentioned previously, chronic regulation of steroidogenesis involves 
transcription of the genes encoding the necessary steroidogenic enzymes. This 
is mediated by alteration of trans-acting factors that bind to the cis-regulatory 
elements within the 5′ regulatory regions of the target genes. Investigation of the 
5′ regulatory regions of the CYP11B gene revealed six cis-acting elements (Ad1–6) 
(Figure 6). The most important cis-elements in the hCYP11B2 promoter are CRE 
at −71/−64 (Ad1), Ad5 at −129/−114, Ad4 at −344/−336, and a cis-element termed 
NGFIB response element 1 (NBRE-1) −766/−759 (Figure 7) [33].
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3.5.2.1 Ad1 (CRE)
The Ad1 element closely resembles a consensus cAMP regulatory element 
(CRE) site. CREs plays an essential role in cAMP-dependent gene expression of a 
wide variety of genes. Proteins, such as the CRE-binding protein (CREB) and the 
highly related activating transcription factors (ATF), bind to CRE sites to initiate 
transcription. CREB binds to DNA as a dimer and has a conserved region of leucine 
residues (leucine zipper) at its C terminus that enables dimerization and sequence 
specific DNA binding [34].
CREB functions not only as a component of a variety of signaling pathways, 
particularly PKA, but also mitogen-activated protein kinases (MAPKs) and CaMKs. 
All these pathways mediate CREB-induced transcription by phosphorylating CREB at 
residue serine 133 [35]. The phosphorylated serine 133 binds another protein referred 
to as the CREB-binding protein (CBP). CBP is a 265-kDa nuclear protein, which 
binds to phosphorylated CREB and allows recruitment and stabilization of the RNA 
polymerase II transcription complex on the promoter of CREB target genes [36].
Using electrophoretic mobility shift assay, the CYP11B2 CRE has been shown to 
bind members of the activating transcription factor (ATF-1 and ATF-2) and CRE-
binding protein (CREB) families. The ability of these transcription factors, par-
ticularly ATF-1 and CREB, to enhance transcription is partially regulated by their 
state of phosphorylation. Thus, one possibility is that activated CaMK I or CaMK IV 
phosphorylates CREB or ATF-1 leading to increased CYP11B2 transcription [28].
3.5.2.2 AD4 (SF-1)
The Ad4 site (CCAAGGTC) is also found to be important in the regulation of 
the CYP11B gene. This Ad4 site or homologous sequences have been identified in the 
regulatory regions of all other steroid P450 genes (CYP11A1, CYP21, CYPI7, CYP11B1, 
Figure 6. 
Schematic diagram of the CYP11B2 promoter with the cis-elements (Ad1–Ad6).
Figure 7. 
Schematic diagram of the most important transcription factor binding sites in the hCYP11B2 
5’UTR. Abbreviations: CREB, cAMP regulatory element response element; SF-1, steroidogenic factor 1; 
COUP-TF, chicken ovalbumin upstream promoter transcription factor; NGFIB, nerve growth factor IB; 
NURRI, nuclear receptor-related 1 protein; NBRE-1, NGFI-B response element.
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CYP11B2, and CYPI9), suggesting an important functional role in steroidogenesis. An 
Ad4-binding protein (Ad4BP) has been identified and cloned from bovine adrenal 
cortex nuclear extract. Ad4BP is a homolog of the steroidogenic factor 1 (SF-1) identi-
fied in the human [37].
SF-1 is an orphan member of the nuclear hormone receptor superfamily, with 
potential phosphorylation sites for cAMP-dependent kinases, CaMK or PKC, sug-
gesting a role for SF-1 in cAMP-dependent transcription. SF-1 is a 53 kDa protein 
consisting of a zinc finger domain and ligand binding/dimerization domain. The 
hydroxyl cholesterols enhance SF-1-dependent transcriptional activity in vitro, 
suggesting that SF-1 is a ligand-activated receptor. However, this is a controversial 
finding and needs further clarification [38].
SF-1 is expressed exclusively in steroidogenic tissues and plays an essential role 
in the development and function of the primary steroidogenic tissues [39]. Within 
the adrenal, SF-1 has been found to play a key role in the transcriptional regulation 
of most of the steroid hydroxylase genes (CYP11A1, CYP21, CYP11B1, CYP17, and 
CYP 19) as well as three β HSD and steroidogenic acute regulatory protein (StAR). 
SF-1 regulation of transcription is mediated by interaction with various co-activator 
proteins, including steroid receptor coactivator 1 (SRC1), glucocorticoid receptor 
interacting protein (GRIP), and also through repressors such as dosage-sensitive 
adrenal hypoplasia congenita of the X chromosome 1 (DAX1) that inhibits SF-1-
mediated steroidogenesis [40].
The Ad4 or SF-1 site has been identified in all steroid P450s based on sequence 
alignments, including at position −351/−343 (AGGTCC) of CYP11B2. Although this 
site binds strongly to SF-1, deletion studies suggest that it is not essential for basal 
or stimulus-induced expression of CYP11B2. In fact, co-expression of CYP11B2 
reporter gene constructs with SF-1 has a negative effect on gene transcription, 
making the regulation of CYP11B2 different to the other steroidogenic genes, StAR, 
CYP11A, CYP11B1, and CYP 17 that are all induced by SF-1. The effects of both 
NGFIB and NURRl on CYP11B2 expression can be inhibited by SF-1 supporting a 
negative effect of SF-1 [33]. Thus, hCYP11B2 expression is regulated quite differ-
ently from genes for other proteins involved in steroid biosynthesis including StAR, 
CYP11A, CYP11B1, and CYP17, which are all positively regulated by SF-1 [41].
3.5.2.3 AD5
Electrophoretic mobility shift assay (EMSA) analysis of the −129/−114 (Ad5) 
element (CTCCAGCCTTGACCTT) has shown that it binds several nuclear pro-
teins, including SF-1 and another orphan nuclear receptor, chicken ovalbumin 
upstream promoter transcription factor (COUP-TF). On the bovine CYP 17 and 
the mouse CYP21 gene, COUP-TF and SF-1 bind competitively to a common site. 
Deletion of this site decreases basal activity by approximately 80% and also reduces 
the maximal response to Ca2+ and cAMP stimulation [42].
3.5.2.4 NBRE
The transcription factors nerve growth factor IB (NGFIB) and nuclear 
receptor-related 1 protein (NURRl) are members of the NGFIB family of orphan 
nuclear receptors that bind to a consensus sequence NGFI-B response element 
(NBRE) (AAAGGTCA). These factors can also bind to the Ad5 element as well 
as a novel NBRE-1 site at −766/−759. Both these transcription factors increase 
CYP11B2 expression by angiotensin II or K+ stimulation. Mutation of the NBRE-1 
site decreases basal expression as well as the response to angiotensin II and K+. 
The Recent Topics in Genetic Polymorphisms
10
Therefore, the CRE, Ad5, and NBRE-1 sites interact to regulate basal transcription 
as well as the response to each signaling pathway (cAMP or Ca2+) [33].
4. Genotypic variants and haplotypes in CYP11B2 gene
Several polymorphisms have been identified in CYP11B2 and are associated 
with enhanced CYP11B2 transcription, increased aldosterone production, and 
the progression of many cardiovascular disorders (Figure 8). About 227 single-
nucleotide polymorphisms (SNPs) have been detected in different population 
worldwide according to National Center for Biotechnology Information (NCBI) 
database (https://www.ncbi.nlm.nih.gov/) [43]. However, only few SNPs are 
evaluated in different studies. The first and most extensively studied polymor-
phism is −344 C/T which exists in the 5′ promoter region of CYP11B2 gene. 
It occupies the putative binding site for the transcription factor SF-1 which is 
responsible for the expression of several enzymes involved in steroid biosynthe-
sis framework in the adrenal cortex. The two alternative bases at this position are 
thymine (T) and cytosine (C) [44]. CYP11B2 −344C/T polymorphism is associ-
ated with increased aldosterone synthesis and secretion in serum [45] or urine 
[46] and increased aldosterone renin ratio [47, 48] with either C allele or T allele 
were suggested to be involved among different studies. The mechanisms that 
stand behind this association are conflicting. Functional studies showed that T 
allele binds to SF-1 with four folds lower affinity than the C allele. This results in 
stimulation of the expression of enzymes responsible for steroidogenesis leading 
to increased aldosterone synthase activity in C allele carriers [41]. However, in 
T allele carrier, the increased aldosterone production was explained by lower 
affinity for SF1 binding leading to the increased availability of this transcription 
factor in other parts of the gene with subsequent activation of the steroidogenic 
acute regulatory gene [45]. On the other hand, others suggest that this poly-
morphism exert its effect via a strong linkage disequilibrium with functional 
polymorphisms in CYP11B1, a substitution (T to C) in codon 75 and (G to A) in 
intron 6 that result in 11 β hydroxylase deficiency [49]. This results in sustained 
elevation of ACTH [50] with subsequent increases in the expression of a number 
of genes required for aldosterone synthesis including StAR, CYP11A, and CYP21 
leading to enhanced aldosterone synthesis [31, 50].
The second polymorphism is a gene intronic conversion (IC) whereby a frag-
ment of the “wild-type (Wt)” intron 2 of CYP11B2 is replaced by the correspond-
ing intronic fragment of CYP11B1 conversion (Conv). Due to the nature of this 
variation and difficulty in genotyping it, its frequency has not been reported in 
Figure 8. 
Common CYP11B2 polymorphisms associated with increased aldosterone production.
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public databases. The −344 T/C and intron conversion polymorphisms are in tight 
linkage disequilibrium and three common haplotypes have been reported: T/Conv 
(38%), C/Wt (45%), and T/Wt (13%), where the first allele corresponds to the 
−344 polymorphism (T or C) and the second to the intron 2 conversion (Wt or 
Conv) [31].
Beside the previously described polymorphisms of CYP11B2, other interesting 
polymorphisms have been reported and associated with increased aldosterone 
production as missense mutation in exon 3, where a lysine is replaced by an argi-
nine (K173R) and CYP11B2 (T4991C) SNP in exon 7 [51]. However, the haplotype 
including −344T and K173 was associated with higher CYP11B2 expression in 
adrenal tissue than the −344C and R173 haplotype [52]. Moreover, other poly-
morphisms have been studied as G5937C and A4550C and were associated with 
heart size [53].
4.1 CYP11B2 genotypic variants and hypertension
Hypertension is a complex progressive cardiovascular disorder, not just a scale 
of threshold blood pressure values, with many causes that result in both functional 
and structural cardiac and vascular system abnormalities that damage the heart, 
kidneys, brain, vasculature, and other organs, and lead to premature morbidity 
and death [54]. Essential hypertension is a multifactorial disorder, predisposed 
by genetic and environmental factors [55]. Growing evidences suggest the poten-
tial role of genetic alteration affecting genes encoding the aldosterone synthesis 
pathway enzymes with associated enhanced aldosterone production resulting in 
progression to essential hypertension [56].
Several polymorphic variants of CYP11B2 have been identified as potential 
genetic contributor in patients with essential hypertension with −344C/T was 
extensively studied among different ethnic groups, with conflicting results. Public 
databases reported that the T allele is more frequent than the C allele in highland-
ers compared with lowlanders Indian [57], African Americans and Japanese 
subjects [48], Caucasian [58], Tamil population [59], Chinese Han population [38], 
Taiwanese females [60], and recently in the Egyptian population [61]. C allele has 
been suggested to be associated with hypertension by Tsukada et al. [62], Kumar 
et al. [63], Ji et al. [64], Li et al. [65], and in the meta-analysis by Cheng et al. [66]. 
No association was detected in the Japanese population [67] and in the meta-analy-
sis by Chen et al. [68]. These discrepancies reflect the influence of different genetic 
and environmental factors as well as the age and gender in geographically separated 
populations [61].
The CYP11B2 gene intronic conversion (IC) was also described in a small study 
of essential hypertensive subjects; the conversion allele frequency was much lower 
in black subjects compared with white [69]. However, several studies proved the 
more frequent association of CYB11B2 −344T/IC haplotype with hypertensive 
subjects than normotensives, especially those with a high aldosterone renin ratio 
(ARR) and increased aldosterone levels in plasma [45, 47], although this finding 
is not supported in all studies [67]. IC has also associated with a better therapeutic 
response to anti-hypertensive treatment [70].
On the other hand, CYP11B2 (K173R) and CYP11B2 (T4991C) polymorphisms 
were found to be associated with hypertension [51, 52]. A strong synergistic effect 
has existed among different genotypes of CYP11B2 C−344T, IC, and K173R poly-
morphisms with the haplotype (−344T-Conv-K173) associated with a higher risk for 
essential hypertension progression [43]. Despite the use of several polymorphisms 
in CYP11B2, their causal relationship with hypertension and inappropriate aldoste-
rone production remains unclear.
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4.2 CYP11B2 genotypic variants and atrial fibrillation
Atrial fibrillation (AF) is the most clinically prevalent type of cardiac arrhyth-
mia which may be precipitated due to the presence of underlying heart disease such 
as valvular dysfunction, ventricular dysfunction, and hypertension. However, AF 
does not exist in some patients with one or more of these risk factors and presents in 
others without any risk factors. Accordingly, the genetic role had been emerged in 
the predisposition for AF. A positive family history of AF in at least one parent was 
suggested by a recent Framingham Heart study on 2243 participants to be associated 
with an 85% increased relative risk for AF [71].
Taking together this genetic role, two types of AF have been identified regarding 
the heredity characteristics as familial and non-familial AF. Recent studies have 
detected several candidate genes which were suggested to be associated with the 
familial AF type such as genes encoding for subunits of potassium or sodium chan-
nels, sarcolipin, connexin 40, endothelial nitric oxide synthase, interleukin 10, and 
RAAS [72].
Association of genetic variants of renin angiotensin aldosterone system 
(RAAS) system with non-familial AF was suggested by Tsai et al. [73] using a 
risk-factor matched design. CYP11B2 −344C/T polymorphism was reported to 
be associated with the susceptibility of AF by Amir et al. [74] in a cohort of 196 
patients with symptomatic systolic heart failure. They found that the −344 CC 
genotype to be a strong independent predictor for AF (adjusted OR 2.35, 95% CI 
1.57–3.51, P = 0.03). Therefore, CYP11B2 −344C/T polymorphism may predispose 
to AF in patients with HF. Another study by Lu et al. [75] on 359 of Han and 
Kazak population with non-valvular AF and 527 non-AF patients as a control 
reported that −344C/T polymorphism of CYP11B2 was associated with AF risk 
as the frequencies of TT genotype, and co-dominant model (CC + TT genotype) 
in Han population and of TT genotype, and dominant model (CT + TT genotype) 
in Kasak population were significantly higher in AF group than in the control 
group. Furthermore, a meta-analysis by Li et al. [76] involving 2758 subjects 
from six distinct studies reported that CYP11B2 T−344C gene polymorphism 
was significantly associated with AF in all genetic models; allelic (OR: 1.26, 
P = 0.0002), recessive (OR: 1.99, P = 0.003), dominant (OR: 0.903, P = 0.036), 
and homozygous (OR: 1.356, 95% CI: 1.130–1.628, P = 0.001), and additive (OR: 
1.153, P = 1.0 × 10−10). On the other hand, no significant association was detected 
by Zhang et al. [77] between different genotype and alleles of −344 T/C polymor-
phism and lone AF patients.
The possible mechanisms for the association of CYP11B2 polymorphism and 
AF are mainly related to increased aldosterone production. Aldosterone exerts 
its effect via direct and indirect ways. Indirect effect of aldosterone on the heart 
arise from its role on increasing blood volume, blood pressure, left ventricular 
pressure, left ventricular hypertrophy, left atrial pressure, and left atrial volume. 
However, aldosterone can directly act on the heart inducing cardiac hypertrophy 
and fibrosis [78, 79] via the proliferation and differentiation of myocardial cells, 
vascular smooth muscle cells, and fibroblasts, leading to a significant increase in 
collagen production. These effects lead to cardiac fibrosis and structural remodel-
ing leading to heart rhythm disorders. Specifically, in the atrium, aldosterone may 
directly or indirectly cause atrial enlargement and fibrosis, leading to structural 
and electrical atrial remodeling resulting in atrial fibrillation. Based on these 
findings, aldosterone antagonists as angiotensin II receptor antagonists may be 
used clinically in the patients with AF to control and minimize the incidence and 
persistence of AF [80].
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4.3 CYP11B2 genotypic variants and coronary artery disease
Coronary artery disease (CAD) is a complex disorder comprised two major sub-
sequent events: coronary atherosclerosis and myocardial infarction (MI). Despite 
the major progress in diagnosis of CAD, the pathogenesis and possible risk factors 
need further evaluation. The classical risk factors including positive family history, 
smoking, high body mass index, and disorders as hyperlipidemia, hypertension, 
and diabetes mellitus have been reported to be responsible for no more than 50% of 
total risk factors for CAD. Accordingly, genetic background seems also to partici-
pate in the predisposition for CAD [81].
Among the different polymorphisms described for CYP11B2 gene, several 
studies have shown that the CYP11B2 gene ˗344T>C polymorphism is associated 
with CAD in different ethnic groups with controversial results. Previous study 
on 201 CAD patients and 201 controls form Italian population have detected that 
CYP11B2 polymorphism and CC genotype were associated with CAD risk in crude 
analysis with borderline significance which is lost by stratification to the confound-
ing factors as smoking and family history [82]. A meta-analysis suggested that the 
−344T>C polymorphism in the CYP11B2 gene might be associated with suscepti-
bility to CAD in Caucasians and Asians [83]. A study on 609 Taiwanese male and 
female subjects who were unrelated and received coronary catheterization found 
that the C/C allele occurred more frequently in females who had CAD, and that it 
was associated with higher left ventricular mass (LVM) and left ventricular end 
diastolic diameter (LVEDD) [84]. Sharma et al. [85] also reported the association 
of the CYP11B2 −344C>T polymorphism with the size of atherosclerotic plaque 
in the carotid artery. Neal et al. [86] suggested that −344C/T polymorphism is a 
cardiovascular risk factor due to its association with LV hypertrophy and decreased 
baroreflex sensitivity which predict the morbidity and mortality rates of MI. Others 
failed to find any significant association of CYP11B2 with CAD in different popula-
tions as in an Indian population and other populations [87–89].
The underlying mechanism by which the CYP11B2 ˗344T>C polymorphism 
can increase the risk for CAD remains unclear. However, it is related to its effect 
on increasing expression of CYP11B2, thereby increasing aldosterone secretion 
[83]. Also, the influence of gene-environment interaction has been involved as 
an etiological factor for CAD risk. Growing evidence has suggested the interac-
tion between ˗344T>C polymorphism and positive smoking for enhanced CAD 
risk [90]. Also, Hautanen et al. [91] detected that smoking and dyslipidemia are 
associated risk factors for non-fatal MI in males who were carriers for CYP11B2 
−344C/T allele.
4.4 CYP11B2 genotypic variants and hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a clinical cardiac dysfunction char-
acterized mainly by hypertrophy of left ventricle. HCM is an autosomal dominant 
disorder and its diagnosis needs to exclude other cardiac or systemic causes of 
increased ventricular wall thickening. HCM comprises different histological 
features as cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. Several 
factors are involved in the pathogenesis of HCM, with the genetic element has 
an upper hand. Mutations and polymorphisms in genes encoding the sarcomere 
proteins and renin-angiotensin-aldosterone system (RAAS) seem to be related to 
the predisposition for left ventricular hypertrophy (LVH) and HCM [92].
Evidences suggested that aldosterone seems to play a major role in the pro-
gression of LVH and HCM as it is produced locally in the heart and CYP11B2 
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mRNA levels show sevenfold increase in the cardiac tissue of HCM patients when 
compared normal cardiac tissue [93]. It exerts its action via stimulation of miner-
alocorticoid receptor resulting in enhancement of myocardial cell hypertrophy, 
progressive myocardial fibrosis leading to ventricular and septal remodeling, and 
hypertrophy, resulting in elevated ventricular mass observed in HCM patients [94, 
95]. Therefore, genetic variations involving CYP11B2 gene might influence the 
structure and function of the left ventricle via increasing aldosterone secretion [93].
Several polymorphisms in the CYP11B2 had been described in the HCM with 
−344C>T and intron 2 conversion have significant associations with left ventricular 
size, mass, and function in different population studies. However, the −344C>T 
promoter polymorphism is a much better predictor of left ventricular size than 
is the intron 2 gene conversion [96]. The −344C>T polymorphism have proved 
to be associated with the risk for HCM progression in many previous studies [93, 
94, 97–99], whereas no association has suggested by other studies [100, 101].This 
controversy extents to the risk allele, which may be the −344C in some studies 
[96, 98–100, 102, 103] or −344T in another study [97]. Moreover, the risk allele for 
increased ventricular size and thickness differs regarding gender as with a study by 
Chai et al., [97] in which the T allele carrier is associated with a significantly higher 
intra-ventricular septum thickness in males, whereas in females, CC genotype carri-
ers had a higher risk for increased intra-ventricular mass thickness, left ventricular 
mass index, and Wigle score.
4.5 CYP11B2 genotypic variants and heart failure
Heart failure (HF) is a cardiac disorder characterized by cardiac remodeling 
with subsequent cardiac dysfunction [104]. It is a multifactorial disease, which is 
precipitated due to underlying cardiac disorders as hypertension, CAD, valvular 
dysfunction, arrhythmia, and cardiomyopathy. Integrated neuronal and hormonal 
elements are involved in the pathogenesis of HF including activation of the sym-
pathetic nervous system and the renin-angiotensin-aldosterone system, and other 
mediators as endothelin, vascular endothelial growth factor, and inflammatory 
cytokines. Based on the previously described neurohormonal factors, therapeutic 
approaches for HF have developed to block these factors including angiotensin-
converting enzyme inhibitors (ACEI), and aldosterone antagonists [105]. Several 
risk and prognostic factors have influenced the progression of chronic congestive 
heart failure (CHF) including age, New York Heart Association (NYHA) class, 
renal function, and comorbidities such as atrial fibrillation, diabetes mellitus, and 
ischemic heart disease [106]. However, genetic elements seem to affect the risk, 
severity, and therapeutic response of HF [107]. CYP11B2 polymorphisms specifi-
cally −344C/T is among these genetic factors and has been associated with the 
susceptibility, therapeutic response, or prognosis of HF.
A study by McNamara et al. [108] was performed on a total of 354 subjects from 
A-HeFT (African American Heart Failure Trial). They detected a higher frequency 
of −344 TT genotypes carriers (61%) than CC genotypes carriers (6.2%) in African 
Americans. Also, the −344 C allele was associated with significantly poorer HF 
hospitalization-free survival and a higher rate of death. Moreover, the therapeutic 
influence of nitric oxide donor (isosorbide dinitrate and hydralazine) was aug-
mented in the presence of the TT genotype.
Another study by Feola et al. [109] on 175 patients from the European conti-
nental ancestry congestive heart failure (CHF) population and revealed that no 
significant differences between −344 CC and −344 TT genotypes carriers regarding 
cardiac output, end-systolic or diastolic left ventricle diameter, left ventricular 
ejection fraction (LVEF), and pro-natriuretic peptide (BNP). Also, −344 C allele 
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carriers have a higher degree of disability (Barthel Index), NYHA class, and a lower 
cardiac index. Moreover, the two groups showed a similar clinical outcomes either 
death or re-hospitalization after 4 years follow up period.
In 107 Black South African patients with dilated cardiomyopathy in functional 
class II–III, Tiago et al. [110] detected that the −344C allele was associated with 
improvement of LVEF after traditional therapy despite it is not related to the 
baseline LVEF as well as left ventricular dimension. Also, the allele distribution has 
proven to be different among races as the C allele was significantly more frequent 
in non-African-American HF patients if compared with African-American patients 
and associated only in the African-American with a lower end-systolic left ventricu-
lar diameter at 1 year follow-up [111]. Moreover, the association of −344C allele 
was confirmed as a risk factor for the progression of AF in a cohort of 194 African-
American HF patients [112].
5. Conclusions
CYP11B2 gene polymorphism is associated with increased cardiovascular risk via 
enhancing aldosterone synthesis and production which acts either systemically or 
locally on the heart. There is a large number of polymorphisms has been identified 
for CYP11B2. Among them, −344C/T polymorphism was extensively studied in 
different ethnic groups and has proved to be associated either solely or synergistic 
with other CYP11B2 polymorphisms in the risk for progression and susceptibility 
of several cardiovascular disorders as hypertension, AF, CAD, cardiomyopathy, 
and HF. Also, CYP11B2 polymorphisms were confirmed as a predictor for survival 
and therapeutic response in some cardiovascular disorders as hypertension and 
HF. Moreover, gene-environment interactions of CYP11B2 were suggested in several 
studies but still need to be confirmed.
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